These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17904355)

  • 1. Molecular targeted therapy of head and neck cancer: review and clinical development challenges.
    Le Tourneau C; Faivre S; Siu LL
    Eur J Cancer; 2007 Nov; 43(17):2457-66. PubMed ID: 17904355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor directed therapy in head and neck cancer.
    Choong NW; Cohen EE
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
    Astsaturov I; Cohen RB; Harari P
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1179-93. PubMed ID: 17020453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of molecularly targeted agents in the primary treatment of squamous cell carcinomas of the head and neck.
    Bernier J
    Hematol Oncol Clin North Am; 2008 Dec; 22(6):1193-208, ix. PubMed ID: 19010268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging molecular targeted therapies in the treatment of head and neck cancer.
    Bozec A; Peyrade F; Fischel JL; Milano G
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
    Gilbert J; Argiris A
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.
    Langer CJ
    Cancer; 2008 Jun; 112(12):2635-45. PubMed ID: 18442098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
    Panikkar RP; Astsaturov I; Langer CJ
    Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New advances in targeted therapies for squamous cell carcinoma of the head and neck.
    Machiels JP; Schmitz S
    Anticancer Drugs; 2011 Aug; 22(7):626-33. PubMed ID: 21048493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review on the treatment of relapsed/metastatic head and neck cancer.
    Ferrari D; Codecà C; Fiore J; Luciani A; Foa P
    Expert Opin Pharmacother; 2009 Nov; 10(16):2625-32. PubMed ID: 19708856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
    Bran B; Bran G; Hörmann K; Riedel F
    Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of antiangiogenic agents in the treatment of head and neck cancer.
    Denaro N; Russi EG; Colantonio I; Adamo V; Merlano MC
    Oncology; 2012; 83(2):108-16. PubMed ID: 22777379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET monitoring of therapy response in head and neck squamous cell carcinoma.
    Schöder H; Fury M; Lee N; Kraus D
    J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.
    Harrington KJ; Kazi R; Bhide SA; Newbold K; Nutting CM
    Indian J Cancer; 2010; 47(3):248-59. PubMed ID: 20587899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecularly targeted therapy in head and neck cancer].
    Le Tourneau C
    Bull Cancer; 2010 Dec; 97(12):1453-66. PubMed ID: 21134823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
    Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
    Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
    Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
    Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.